无法解释的儿科肝病的临床特征和遗传原因
Yuan Chen1, Zhi-Yi Wang2,3,4, Bao-Qi Chen1
1Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China.
World journal of hepatology
|November 3, 2025
概括
全外体测序 (WES) 显著有助于诊断无法解释的儿科肝病,识别遗传原因以指导个性化治疗并改善患者的治疗结果.
科学领域:
- 儿科肝病学 儿科肝病学
- 临床遗传学 临床遗传学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 儿童中无法解释的肝病的发病率增加.
- 全外体测序 (WES) 显示出诊断潜力,但需要进一步研究.
研究的目的:
- 调查未解释的儿科肝病的临床特征和遗传基础.
- 改善患儿的诊断和治疗策略.
主要方法:
- 对80名患有不明原因肝病的儿童进行了回顾性分析,根据肝酶升高或胆固醇定位分类.
- 在患者和他们的父母身上进行全外体测序 (WES).
主要成果:
- 在57.5%的患者 (46/80) 中,WES产生了遗传结果.
- 52.5% (42/80) 具有致病性或可能致病性变异,包括13种新型变异.
- 在两组患者中都发现了19种不同的基因突变.
结论:
- 整体外体测序 (WES) 显著改善了无法解释的儿科肝病的病因诊断.
- 来自WES的遗传发现促进了量身定制的治疗计划和更好的预后.
相关概念视频
Inborn Errors of Metabolism
690
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
690
Pharmacokinetics in Pediatric Patients: Drug Metabolism
185
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
185
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
239
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
239


